

# CITATION REPORT

List of articles citing

## Trastuzumab-containing regimens for metastatic breast cancer

DOI: 10.1002/14651858.cd006242.pub2  
The Cochrane Library, 2014, , CD006242.

**Source:** <https://exaly.com/paper-pdf/59051519/citation-report.pdf>

**Version:** 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
108	Treating metastatic breast cancer: the evidence for targeted therapy. <b>2014</b> , ED000083		
107	Trastuzumab for HER2+ breast cancer: more cardiac toxicities. <b>2014</b> , 1514, 5-5		
106	Validation and Development of a Modified Breast Graded Prognostic Assessment As a Tool for Survival in Patients With Breast Cancer and Brain Metastases. <b>2015</b> , 33, 2239-45		78
105	Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity. <b>2015</b> , 48, 223-35		80
104	Cancer Stem Cells Sensitivity Assay (STELLA) in Patients with Advanced Lung and Colorectal Cancer: A Feasibility Study. <b>2015</b> , 10, e0125037		7
103	Targeted agents for cancer treatment during pregnancy. <b>2015</b> , 41, 301-9		61
102	Systems biology approaches to adverse drug effects: the example of cardio-oncology. <b>2015</b> , 12, 718-31		64
101	Meta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents. <b>2016</b> , 24, 4057-74		12
100	Neurological sequelae of cancer immunotherapies and targeted therapies. <b>2016</b> , 17, e529-e541		59
99	The Effect of Treatment Advances on the Mortality Results of Breast Cancer Screening Trials: A Microsimulation Model. <b>2016</b> , 164, 236-43		29
98	Targeted chemotherapy with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in metastatic breast cancer: which benefit for which patients?. <b>2016</b> , 8, 209-29		22
97	Clinical Perspectives on Targeting Therapies for Personalized Medicine. <b>2016</b> , 102, 79-114		5
96	Precision targeted therapy of ovarian cancer. <b>2016</b> , 243, 250-268		42
95	Clinical Utility of Routine Cardiac Monitoring in Breast Cancer Patients Receiving Trastuzumab. <b>2016</b> , 50, 712-7		8
94	The Tokuhashi score: effectiveness and pitfalls. <b>2016</b> , 25, 673-8		38
93	The Japanese Breast Cancer Society Clinical Practice Guideline for systemic treatment of breast cancer, 2015 edition. <b>2016</b> , 23, 329-42		24
92	Risk of severe cardiotoxicity following treatment with trastuzumab: a meta-analysis of randomized and cohort studies of 29,000 women with breast cancer. <b>2016</b> , 11, 123-40		60

91	The dual mobility cup in muscular skeletal oncology: rationale and indications. <b>2017</b> , 41, 447-453	7
90	Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer. <b>2017</b> , 143, 1255-1262	15
89	Use and outcomes of targeted therapies in early and metastatic HER2-positive breast cancer in Australia: protocol detailing observations in a whole of population cohort. <b>2017</b> , 7, e014439	13
88	Improved systemic treatment for early breast cancer improves cure rates, modifies metastatic pattern and shortens post-metastatic survival: 35-year results from the Munich Cancer Registry. <b>2017</b> , 143, 1701-1712	23
87	Phase Ib dose-finding trial of lapatinib plus pegylated liposomal doxorubicin in advanced HER2-positive breast cancer. <b>2017</b> , 79, 863-871	12
86	Expression and function of MutT homolog 1 in distinct subtypes of breast cancer. <b>2017</b> , 13, 2161-2168	17
85	Cardiotoxicity From Human Epidermal Growth Factor Receptor-2 (HER2) Targeted Therapies. <b>2017</b> , 6,	41
84	MPZL1 forms a signalling complex with GRB2 adaptor and PTPN11 phosphatase in HER2-positive breast cancer cells. <b>2017</b> , 7, 11514	11
83	Dose-escalated radiation therapy is associated with better overall survival in patients with bone metastases from solid tumors: a propensity score-matched study. <b>2017</b> , 6, 2087-2097	4
82	Older cancer patients in cancer clinical trials are underrepresented. Systematic literature review of almost 5000 meta- and pooled analyses of phase III randomized trials of survival from breast, prostate and lung cancer. <b>2017</b> , 51, 113-117	22
81	Prevention of Cardiotoxicity in the Cancer Patient. <b>2017</b> , 11, 1	0
80	Next-Generation Sequencing in Glioblastoma Personalized Therapy. <b>2017</b> , 161-190	1
79	Evolution of anti-HER2 therapies for cancer treatment. <b>2017</b> , 59, 1-21	52
78	Association between obesity and trastuzumab-related cardiac toxicity in elderly patients with breast cancer. <b>2017</b> , 8, 79289-79297	11
77	Safety Profile of Anticancer and Immune-Modulating Biotech Drugs Used in a Real World Setting in Campania Region (Italy): BIO-Cam Observational Study. <b>2017</b> , 8, 607	22
76	Congestive Heart Failure During Osimertinib Treatment for Epidermal Growth Factor Receptor (EGFR)-mutant Non-small Cell Lung Cancer (NSCLC). <b>2017</b> , 56, 2195-2197	16
75	Polyphenols as Promising Drugs against Main Breast Cancer Signatures. <b>2017</b> , 6,	39
74	Risk Factors and Preventions of Breast Cancer. <b>2017</b> , 13, 1387-1397	389

73	Single institution validation of a modified graded prognostic assessment of patients with breast cancer brain metastases. <b>2018</b> , 7, 25-34	5
72	Minimizing inequality in access to precision medicine in breast cancer by real-time population-based molecular analysis in the SCAN-B initiative. <b>2018</b> , 105, e158-e168	18
71	Cardiovascular Risk in Cancer Survivors. <b>2018</b> , 20, 47	12
70	Disparities in Breast Cancer: Private Patients Have Better Outcomes Than Public Patients. <b>2018</b> , 42, 727-735	8
69	Analysis of Alterations in Pan-Cancer Adult and Pediatric Malignancies: Implications for NTRK-Targeted Therapeutics. <b>2018</b> , 2018,	112
68	Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) - Part 2 with Recommendations for the Therapy of Primary, Recurrent and Advanced Breast Cancer. <b>2018</b> , 78, 1056-1088	44
67	Moving Breast Cancer Therapy up a Notch. <b>2018</b> , 8, 518	33
66	Patients who achieved long-term clinical complete response and subsequently terminated multidisciplinary and anti-HER2 therapy for metastatic breast cancer: A case series. <b>2018</b> , 52, 125-131	1
65	Triple Negative Breast Cancer Depends on Sphingosine Kinase 1 (SphK1)/Sphingosine-1-Phosphate (S1P)/Sphingosine 1-Phosphate Receptor 3 (S1PR3)/Notch Signaling for Metastasis. <b>2018</b> , 24, 1912-1923	31
64	Sex Steroids and Incident Cardiovascular Disease in Post-Menopausal Women: New Perspective on an Old Controversy. <b>2018</b> , 71, 2567-2569	2
63	Chemotherapeutic Drugs and Mitochondrial Dysfunction: Focus on Doxorubicin, Trastuzumab, and Sunitinib. <b>2018</b> , 2018, 7582730	145
62	Chemotherapeutic-Induced Cardiovascular Dysfunction: Physiological Effects, Early Detection-The Role of Telomerase to Counteract Mitochondrial Defects and Oxidative Stress. <b>2018</b> , 19,	9
61	Pertuzumab and Trastuzumab Emtansine for Human Epidermal Growth Factor Receptor-2-Positive Metastatic Breast Cancer: Contemporary Population-Based Outcomes. <b>2019</b> , 13, 1178223419879429	4
60	Trastuzumab treatment after progression in HER2-positive metastatic breast cancer following relapse of trastuzumab-based regimens: a meta-analysis. <b>2019</b> , 11, 4699-4706	2
59	Heart Failure and Cancer: Mechanisms of Old and New Cardiotoxic Drugs in Cancer Patients. <b>2019</b> , 5, 112-118	27
58	Biomarkers for Breast Cancer Treatment. <b>2019</b> , 115-124	
57	HER2+ breast cancer treatment and cardiotoxicity: monitoring and management. <b>2019</b> , 177, 237-250	41
56	ene copy numbers as prognostic factors in HER2-positive metastatic breast cancer treated with trastuzumab. <b>2019</b> , 17, 3371-3381	6

55	Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer. <b>2019</b> , 7, 90	40
54	Cardiac outcomes of trastuzumab therapy in patients with HER2-positive breast cancer and reduced left ventricular ejection fraction. <b>2019</b> , 175, 239-246	19
53	The comparative efficacy and risk of harms of the intravenous and subcutaneous formulations of trastuzumab in patients with HER2-positive breast cancer: a rapid review. <b>2019</b> , 8, 321	6
52	CD4 T-cell immune stimulation of HER2 + breast cancer cells alters response to trastuzumab in vitro. <b>2020</b> , 20, 544	0
51	Prognosis of HER2-positive pregnancy-associated breast cancer: Analysis from the French CALG (Cancer Associé La Grossesse) network. <b>2020</b> , 54, 311-318	2
50	Dietary Phenolics against Breast Cancer. A Critical Evidence-Based Review and Future Perspectives. <b>2020</b> , 21,	22
49	Cardioncological Approach for Trastuzumab Therapy in Breast Cancer Patients With Cardiotoxicity: Impact on Adherence and Clinical Outcome. <b>2020</b> , 11, 1190	2
48	Cardiovascular Toxicity of Targeted Therapies for Cancer: An Overview of Systematic Reviews. <b>2020</b> , 4, pkaa076	7
47	Patterns of Biomarker Use in Cancer Treatment Among Medical Oncologists in the Philippines. <b>2020</b> , 6, 1593-1608	0
46	Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBR06-146 (EMERALD)). <b>2020</b> , 31, 201	5
45	Dual HER2 Blockade versus a Single Agent in Trastuzumab-Containing Regimens for HER2-Positive Early Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <b>2020</b> , 2020, 5169278	4
44	Biomarkers for HER2-positive metastatic breast cancer: Beyond hormone receptors. <b>2020</b> , 88, 102064	20
43	Translational issues for mitoprotective agents as adjunct to reperfusion therapy in patients with ST-segment elevation myocardial infarction. <b>2020</b> , 24, 2717-2729	22
42	Invasive breast cancer over four decades reveals persisting poor metastatic outcomes in treatment resistant subgroup - the "ATRESS" phenomenon. <b>2020</b> , 50, 39-48	6
41	Impact of Stopping Trastuzumab in Early Breast Cancer: A Population-Based Study in Ontario, Canada. <b>2020</b> , 112, 1222-1230	11
40	Osimertinib-induced cardiac failure with QT prolongation and torsade de pointes in a patient with advanced pulmonary adenocarcinoma. <b>2021</b> , 10, 68-71	5
39	Trends in Phase II Trials for Cancer Therapies. <b>2021</b> , 13,	3
38	MicroRNA-130a Increases and Predicts Cardiotoxicity during Adjuvant Chemotherapy in Human Epidermal Growth Factor Receptor-2-Positive Breast Cancer. <b>2021</b> , 24, 153-163	4

37	Immunohistochemical HER2 score correlates with response to neoadjuvant chemotherapy in HER2-positive primary breast cancer. <b>2021</b> , 186, 667-676	2
36	Impact of tumor cellularity on the HER2 amplification assay by OncoScan <sup>®</sup> in breast cancer. <b>2021</b> , 28, 977-982	
35	PROTACs: A Hope for Breast Cancer Patients?. <b>2021</b> ,	0
34	Etiology and management of hypertension in patients with cancer. <b>2021</b> , 7, 14	9
33	Polyphenols Modulating Effects of PD-L1/PD-1 Checkpoint and EMT-Mediated PD-L1 Overexpression in Breast Cancer. <b>2021</b> , 13,	3
32	Prolonged Response to HER2-Directed Therapy in Three Patients with HER2-Amplified Metastatic Carcinoma of the Biliary System: Case Study and Review of the Literature. <b>2021</b> , 26, 640-646	1
31	Changes in Overall Survival over Time for Patients with de novo Metastatic Breast Cancer. <b>2021</b> , 13,	1
30	Real-World Clinical Outcomes of Biosimilar Trastuzumab (CT-P6) in HER2-Positive Early-Stage and Metastatic Breast Cancer. <b>2021</b> , 11, 689587	3
29	Current approaches to the treatment of HER2-positive breast cancer with brain metastases. <b>2021</b> , 17, 27-34	1
28	Landmark trials in the medical oncology management of metastatic breast cancer. <b>2021</b> , 48, 246-258	1
27	Fever and breast cancer: A critical review of the literature and possible underlying mechanisms. <b>2021</b> , 40, 117-131	
26	Prognostic Factors in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Advanced Breast Cancer: A Systematic Literature Review. <b>2021</b> , 13, 6537-6566	3
25	Long-Term Outcomes of a Randomized Study of Neoadjuvant Induction Dual HER2 Blockade with Trastuzumab and Lapatinib Followed by Weekly Paclitaxel Plus Dual HER2 Blockade for HER2-Positive Primary Breast Cancer (Neo-Lath Study). <b>2021</b> , 13,	0
24	Adverse Drug Reactions with HER2-Positive Breast Cancer Treatment: An Analysis from the Italian Pharmacovigilance Database. <b>2021</b> , 1	2
23	Breast cancer treatment-related cardiovascular disturbances: advocacy for a watchful attitude in this never-ending story. <b>2021</b> , 1-13	
22	Comparisons of Treatment for HER2-Positive Breast Cancer between Chinese and International Practice: A Nationwide Multicenter Epidemiological Study from China. <b>2021</b> , 2021, 6621722	0
21	Pertuzumab and Trastuzumab Combination with Concomitant Locoregional Radiotherapy for the Treatment of Breast Cancers with HER2 Receptor Overexpression. <b>2021</b> , 13,	3
20	Molecules and Mechanisms to Overcome Oxidative Stress Inducing Cardiovascular Disease in Cancer Patients. <b>2021</b> , 11,	8

19	The Clinical Efficacy and Cardiotoxicity of Fixed-Dose Monthly Trastuzumab in HER2-Positive Breast Cancer: A Single Institutional Analysis. <b>2016</b> , 11, e0151112	7
18	Effectiveness of second-line anti-HER2 treatment in HER2-positive metastatic breast cancer patients previously treated with trastuzumab: A real-world study. <b>2020</b> , 32, 361-369	1
17	Gastrointestinal cancers in the era of theranostics: Updates and future perspectives. <b>2015</b> , 21, 8473-7	4
16	Targeted approaches for HER2 breast cancer therapy: News from nanomedicine?. <b>2014</b> , 3, 72	6
15	Metastatic HER2+ Breast Cancer: A Potentially Curable Disease?. <b>2017</b> , 9, e1654	0
14	Actualidades en el manejo sistémico del cáncer de mama. <b>2020</b> , 10, 71-82	
13	Trends in Phase II trials for cancer therapies.	
12	Bridging academic science and clinical research in the search for novel targeted anti-cancer agents. <b>2015</b> , 12, 316-27	3
11	The impact of hormone receptor on the clinical outcomes of HER2-positive breast cancer: a population-based study.. <b>2022</b> , 27, 707	
10	Evaluation of left atrial remodeling using cardiovascular magnetic resonance imaging in breast cancer patients treated with adjuvant trastuzumab.. <b>2022</b> , 1	0
9	Cardiotoxicity of Non-Anthracycline Cancer Chemotherapy Agents.. <b>2022</b> , 9,	2
8	Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival.. <i>ESMO Open</i> , <b>2022</b> , 7, 100409	6 0
7	Survival after neoadjuvant therapy with trastuzumab-lapatinib and chemotherapy in patients with HER2-positive early breast cancer: a meta-analysis of randomized trials.. <i>ESMO Open</i> , <b>2022</b> , 7, 100433	6 3
6	Evaluating Trastuzumab in the treatment of HER2 positive breast cancer. <i>Histology and Histopathology</i> , <b>2020</b> , 35, 1059-1075	1.4 1
5	Cardiac Monitoring and Heart Failure in Advanced Breast Cancer Patients Treated With Trastuzumab in Ontario, Canada. <i>Frontiers in Cardiovascular Medicine</i> , <b>2022</b> , 9,	5.4 0
4	Breast cancer liver metastasis: Pathogenesis and clinical implications. 12,	0
3	The Present and Future of Clinical Management in Metastatic Breast Cancer. <b>2022</b> , 11, 5891	0
2	CDk Inhibitor for Treatment of Breast Cancer. <b>2023</b> , 313-333	0

- 1 Effects of trastuzumab and trastuzumab emtansine on corrected QT interval and left ventricular ejection fraction in patients with metastatic (HER2+) breast cancer. **2023**, 75,

○